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RANITIDINE AND OMEPRAZOLE EFFECT ON SERUM PHOSPHORUS IN
HEMODIDLYSIS PATIENTS
Elbohy D1, El-hamamsy M2, EL- sharkawy M2
1MSA University, Cairo, Egypt, 2Ain Shams University, Cairo, Egypt
OBJECTIVES: To evaluate the effect of Ranitidine or Omeprazole in combination
with CaCo3(as a phosphate binder) versus phosphate binders alone on the serum
phosphorus level (PO4) in patients performing renal dialysis METHODS: Subjects
were at National Institute of Urology and Nephrology (N.I.U.N) and Ain Shams
University Specialized Hospital (A.S.U.S.H), Cairo,Egypt. They were classified into
three groups .Group I (38 subjects) served as control group in which they
receivedCaCo3alone. Group II(39subjects) administrated CaCo3(2 gm-12gm three
times daily) with Ranitidine (150mg twice daily).Group III(31subjects)received the
same dose of CaCo3with Omeprazole (20 mg once daily).Blood samples were col-
lected monthly for six months during the hemodialysis sessions. RESULTS: The
obtained data revealed that patients in group II showed marked increase in serum
(PO4) level at 4th, 5th and 6th months with significant increase in Calcium- Phos-
phorus product (CaxP). Significant decrease in serum level of Ca andAlkaline phos-
phatase (ALP). No significant change in serum PTH level .While in group III, the
results show no significant change in serum level of Ca, PO4, PTH, and (CaxP) value
with a significant decrease in serum ALP. CONCLUSIONS: Ranitidine co-adminis-
tration with CaCo3 may aggravate hyperphosphatemia.Omeprazole co-adminis-
trationwith CaCo3may have a beneficial role inminimizing complications in those
patients.
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THE EFFECT OF PREVENTION USING DRUG THERAPY ON KIDNEY STONE
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OBJECTIVES: Surgical intervention (extracorporeal shockwave lithotripsy (ESWL),
ureteroscopic lithotripsy (URSL), or staged intervention) is necessary when the
likelihood of spontaneous passage of kidney stones is low or complications arise.
Secondary prevention can involve drug therapy with allopurinol, thiazides, or po-
tassium citrate, as well as metabolic evaluation to guide drug therapy. Our objec-
tive is to evaluate the impact of drug therapy in lowering the risk of kidney stone
recurrence. METHODS: This retrospective cohort study was conducted in Kaiser
Permanente Southern California. Adult patients with a diagnosis of kidney stones
and who underwent surgery between July 1, 2006 and June 30, 2008 were selected.
Patients were screened for 2.5 years of continuous membership before their sur-
gery [index] date without evidence of previous surgery. Patients were followed
until they experienced a recurrence of kidney stones, dis-enrolled from the health
plan, death, or the end of study’s data period. A cox proportional hazardmodel was
utilized to estimate the effect of drug therapy on kidney stone recurrence, control-
ling for other risk factors and the use of metabolic evaluation. RESULTS: A total of
2881 patients met inclusion criteria. Only 1159 (40.2%) patients received drug ther-
apy, while 574 (19.9%) patients receivedmetabolic evaluation within 1.5 months of
the index date. ESWL was used in 46.6% of patients, URSL in 48.4% of patients, and
staged intervention in 5% of patients. 819 (28%) patients had a recurrence (average
follow-up: 37.0 months). Drug therapy significantly reduced the rate of recurrence
of kidney stone (HR: 0.59, 95% CI0 .49-0.71, p.0001) relative to no drug therapy.
The significant risk factors for recurrence were the use of ESWL and staged inter-
vention (both vs. URSL), prior use of study drugs or topiramate, and having baseline
diarrhea/mal-absorption. CONCLUSIONS: Medical prevention using drug therapy
had a significant preventive effect on kidney stone recurrence following surgery.
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A SYSTEMATIC REVIEW AND META-ANALYSIS OF SOLIFENACIN SUCCINATE
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OBJECTIVES: To carry out a systematic review and meta-analysis of solifenacin
succinate and trospium chloride, two widely used anticholinergic drugs in the
treatment of overactive bladder, in order to provide evidence on which formulary
and prescribing decisions can be based upon. METHODS: Electronic searches of
PubMed, the Cochrane Library, other electronic search engines, as well as manual
searches of relevant papers, for randomised controlled trials comparing solifena-
cin succinate and trospium chloride with one another, with other anticholinergic
drugs, or with placebo, from 2003 to October 2011 yielded 260 titles and abstracts
from which 8 papers were included in the meta-analysis. Five were trials compar-
ing solifenacin 5mg and 10mgwith placebo,while 3were trials of trospiumchloride
20mg (twice a day) immediate release (IR) or 60mg extended release (ER) versus
placebo. No direct head to head clinical trials comparing trospium and solifenacin
with each other were found. Hence the method of adjusted indirect comparison
was used to compare them. RESULTS: There was greater improvement from base-
line with both solifenacin 5mg and solifenacin 10mg compared to trospium ER in
daily micturitions: mean differences (md) (95% CI) -0.89 (-1.14, -0.70) and -1.25
(-1.66, -0.95) respectively, and -0.93 (-1.39, -0.62), and -1.31 (-2.00, -0.85) when com-
pared to trospium IR. Similarly for urinary urgency incontinence: md (95% CI) were
-0.78 (-1.43, -0.42) in favour of solifenacin 5mg compared to trospium ER, -0.75
(-1.46, -0.38) in favour of solifenacin 10mg versus trospiumER and -1.55 (-2.17, -1.11)
and -1.5 (-2.30, -0.98) comparing solifenacin 5mg and 10mg to trospium IR. There
were no statistically significant differences in discontinuations due to adverse
events including both dry mouth and constipation. CONCLUSIONS: Solifenacin
appears to bemore efficacious than trospium (IR and ER) in ameliorating the symp-
toms associated with overactive bladder syndrome but shows no statistically sig-
nificant differences in common safety and tolerability issues.
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PHOSPHATE BINDERS
Yusuf AA1, St. Peter W2
1University of Minnesota, Minneapolis, MN, USA, 2United States Renal Data System,
Minneapolis, MN, USA
OBJECTIVES: The purpose of this study was to 1) determine medication adherence
in hemodialysis patients initiated on either calcium acetate or sevelamar, and 2)
determine the association between adherence to phosphate binder therapy and
age in hemodialysis patients.METHODS: Using records from incident hemodialy-
sis patients in the Centers for Medicare and Medicaid Services End-Stage Renal
Disease database linked with Medicare Part D data, we compiled information on
patients treated with phosphate binders (1/2007 - 6/2009). We included patients
thatwere treatedwith either calciumor sevelamar. Prescription refill records in the
6-month post-index periodwere assessed and twomeasures of adherence; propor-
tions of days covered (PDC) and total gap were computed. A PDC of  80% was
considered adherent. RESULTS:A total of 7299 patients that did not switch therapy
and survived at least six months from the index phosphate binder date were in-
cluded in this analysis. Compared to calcium patients, sevelamar patients had a
significantly higher mean PDC, a significantly lower mean total gap, were signifi-
cantly more likely to be adherent; and were significantly less likely to have gaps in
medication possession during the first 6 months of pharmacotherapy (P0.05).
After adjustment for multiple factors, older patients (age  75 at dialysis initia-
tion) had a significantly higher mean PDC, a significantly lower mean total gap,
were significantly more likely to be adherent; and were significantly less likely to
have gaps in medication possession during the follow up period than did younger
patients (age75) (P0.05). CONCLUSIONS:Overall about one-third of the patients
included in this study were adherent at 6 months of initiation of phosphate binder
therapy (PDC80%). Patients treated with sevelamar were more adherent than
those treated with calcium, and they had fewer gaps in medication possession.
Older patients were more adherent than younger patients.
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OBJECTIVES: Erythropoiesis-stimulating agents (ESA) are used in patients who de-
velop anemia secondary to end-stage renal disease (ESRD). Increase in incidence of
thrombosis and death in adult ESRD patients resulted in a warning by the FDA to
adjust ESA doses to maintain target hemoglobin of 12 g/dL. Children with ESRD
also develop anemia that ESAs are used to treat. The objective of this study was to
determine cardiovascular outcomes associated with ESA use in pediatric ESRD
patients.METHODS: This is a retrospective study using the USRDS database from
2004-2008. Children 0-19 years oldwith a diagnosis of anemia (hemoglobin 5% for
age and sex) were included. Patients with evidence of ESA administration prior to
dialysis were excluded. Patients were classified as having received ESA or no-ESA.
Cardiovascular events (ischemic heart disease, stroke and embolism) were identi-
fied using ICD-9 codes. Logistic regression with cardiovascular event as the depen-
dent variable was undertaken. Covariates included diabetes, hypertension and
hypercholesterolemia. RESULTS: Of 2,138,876 patients, 3,226 met the inclusion
criteria, 1,302 with ESA and 1,924 without. The mean age at time of anemia diag-
nosis was 14.8 years and 14.06 years in the ESA and no-ESA groups, respectively. A
cardiovascular event occurred in 277 patients in the ESA group versus 37 patients in
the no-ESA group. In the regression model, odds ratios for cardiovascular event
were 6.71 (95% CI 4.62-9.73) for ESA therapy and 4.27 (95% CI 3.17-5.76) for patients
with hypertension.CONCLUSIONS: ESA therapy in pediatric ESRDpatients appears
to increase risk of a cardiovascular event in pediatric ESRD patients. Further study
should be undertaken to confirm these results.
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NOCTURIA AND THE RISK OF FALLS, FRACTURES, AND SLEEP DISTURBANCE: A
SYSTEMATIC REVIEW AND META-ANALYSIS
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OBJECTIVES: To assess the strength of association between nocturia and falls,
fractures, and sleep disturbance in the published literature. METHODS: A meta-
analysis was conducted based on a search of PUBMed and EMBASE from inception
to October 2011. Studies were included if they reported risk of falls, fractures, or
magnitude of sleep disturbance in relation to nocturia status and were in the Eng-
lish language. Data was collected using a standardized data collection instrument.
The pooled odds ratio (OR) was calculated using a random-effects model. A quali-
tative synthesis was conducted in regards to the impact nocturia has on sleep.
RESULTS: A total of 9 citations examining falls and fractures with respect to noc-
turia were identified. One was a duplicate, 3 were review articles, and 1 study only
focused on qualitative outcomes. The pooled adjusted OR for falls was 1.40 (95%
confidence interval (CI), 1.161-1.688). The OR for fractures was 1.23 (95% CI, 1.04-
1.45). Forty-four studies examined the relationship between nocturia and sleep.
Eleven studies were excluded due to the effect modification that sleep disorders
have on nocturia. Other reasons for exclusion included 11 articles due to irrelevant
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